Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Gains from Investment Securities (2016 - 2025)

Lexaria Bioscience's Gains from Investment Securities history spans 10 years, with the latest figure at $7331.0 for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 7.52% year-over-year to $7331.0; the TTM value through Nov 2025 reached $28540.0, up 1.4%, while the annual FY2025 figure was $1.5 million, 57.09% up from the prior year.
  • Gains from Investment Securities for Q4 2025 was $7331.0 at Lexaria Bioscience, up from $7199.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $474436.0 in Q2 2023 and bottomed at $3662.0 in Q4 2023.
  • The 5-year median for Gains from Investment Securities is $9471.0 (2021), against an average of $111381.8.
  • The largest annual shift saw Gains from Investment Securities surged 3182.61% in 2023 before it tumbled 98.38% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $9385.0 in 2021, then increased by 19.38% to $11204.0 in 2022, then plummeted by 67.32% to $3662.0 in 2023, then skyrocketed by 86.18% to $6818.0 in 2024, then increased by 7.52% to $7331.0 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Gains from Investment Securities are $7331.0 (Q4 2025), $7199.0 (Q3 2025), and $7069.0 (Q2 2025).